

Genetic fine-mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci

Kyle J Gaulton^{1,2,161}, Teresa Ferreira^{1,161}, Yeji Lee^{3,161}, Anne Raimondo^{4,161}, Reedik Mägi^{5,161}, Michael E Reschen^{6,161}, Anubha Mahajan¹, Adam Locke³, N William Rayner^{1,4,7}, Neil Robertson^{1,4}, Robert A Scott⁸, Inga Prokopenko⁹, Laura J Scott³, Todd Green¹⁰, Thomas Sparso¹¹, Dorothee Thuillier¹², Loic Yengo¹², Harald Grallert^{13,14,15}, Simone Wahl^{13,14,15}, Mattias Frånberg^{16,17,18}, Rona J Strawbridge¹⁶, Hans Kestler^{19,20}, Himanshu Chheda²¹, Lewin Eisele²², Stefan Gustafsson²³, Valgerdur Steinthorsdottir²⁴, Gudmar Thorleifsson²⁴, Lu Qi^{25,26,27,28}, Lennart C Karssen²⁹, Elisabeth M van Leeuwen²⁹, Sara M Willems^{8,29}, Man Li³⁰, Han Chen^{31,32}, Christian Fuchsberger³, Phoenix Kwan³, Clement Ma³, Michael Linderman³³, Yingchang Lu³⁴, Soren K Thomsen⁴, Jana K Rundle⁴, Nicola L Beer^{1,4}, Martijn van de Bunt^{1,4}, Anil Chalisey⁶, Hyun Min Kang³, Benjamin F Voight³⁵, Goncalo R Abecasis³, Peter Almgren³⁶, Damiano Baldassarre^{37,38}, Beverley Balkau^{39,40}, Rafn Benediktsson^{41,42}, Matthias Blüher^{43,44}, Heiner Boeing⁴⁵, Lori L Bonnycastle⁴⁶, Erwin P Borringer⁴⁷, Noël P Burt¹⁰, Jason Carey¹⁰, Guillaume Charpentier⁴⁸, Peter S Chines⁴⁶, Marilyn C Cornelis⁴⁹, David J Couper⁵⁰, Andrew T Crenshaw¹⁰, Rob M van Dam^{26,51}, Alex SF Doney^{52,53}, Mozghan Dorkhan⁵⁴, Sarah Ekins⁷, Johan G Eriksson^{55,56,57,58}, Tonu Esko^{5,59,60}, Elodie Eury⁶¹, João Fadista³⁶, Jason Flannick¹⁰, Pierre Fontanillas¹⁰, Caroline Fox^{62,63}, Paul W Franks^{26,36,64,65}, Karl Gertow¹⁶, Christian Gieger^{13,14}, Bruna Gigante⁶⁶, Omri Gottesman⁴⁷, George B Grant¹⁰, Niels Grarup¹¹, Christopher J Groves⁴, Maija Hassinen⁶⁷, Christian T Have¹¹, Christian Herder^{68,69}, Oddgeir L Holmen⁷⁰, Astradur B Hreidarsson⁴², Steve E Humphries⁷¹, David J Hunter^{25,26,27,72}, Anne U Jackson³, Anna Jonsson³⁶, Marit E Jørgensen⁷³, Torben Jørgensen^{74,75,76}, Wen-Hong L Kao^{30,160}, Nicola D Kerrison⁸, Leena Kinnunen⁵⁵, Norman Klopp^{13,77}, Augustine Kong²⁴, Peter Kovacs^{43,44}, Peter Kraft^{25,32,72}, Jasmina Kravic³⁶, Cordelia Langford⁷, Karin Leander⁶⁶, Liming Liang^{25,32}, Peter Lichtner⁷⁸, Cecilia M Lindgren^{1,10}, Eero Lindholm³⁶, Allan Linneberg^{74,79,80}, Ching-Ti Liu³¹, Stéphane Lobbens⁶¹, Jian'an Luan⁸, Valeriya Lyssenko^{36,73}, Satu Männistö⁵⁵, Olga McLeod¹⁶, Julia Meyer⁸¹, Evelin Mihailov⁵, Ghazala Mirza⁸², Thomas W Mühleisen^{83,84,85}, Martina Müller-Nurasyid^{81,86,87,88}, Carmen Navarro^{89,90,91}, Markus M Nöthen^{83,84}, Nikolay N Oskolkov³⁶, Katharine R Owen^{4,92}, Domenico Palli⁹³, Sonali Pechlivanis²², Leena Peltonen^{7,10,21,55,160}, John RB Perry⁸, Carl GP Platou^{70,94}, Michael Roden^{68,69,95}, Douglas Ruderfer⁹⁶, Denis Rybin⁹⁷, Yvonne T van der Schouw⁹⁸, Bengt Sennblad^{16,17}, Gunnar Sigurðsson^{42,99}, Alena Stančáková¹⁰⁰, Gerald Steinbach¹⁰¹, Petter Storm³⁶, Konstantin Strauch^{81,87}, Heather M Stringham³, Qi Sun^{26,27}, Barbara Thorand^{14,15}, Emmi Tikkanen^{21,102}, Anke Tonjes^{43,44}, Joseph Trakalo¹, Elena Tremoli^{37,38}, Tiinamaija Tuomi^{21,58,103,104}, Roman Wennauer¹⁰⁵, Steven Wiltshire^{1,160}, Andrew R Wood¹⁰⁶, Eleftheria Zeggini⁷, Ian Dunham¹⁰⁷, Ewan Birney¹⁰⁷, Lorenzo Pasquali^{108,109,110}, Jorge Ferrer^{111,112}, Ruth JF Loos^{8,34,47,113}, Josée Dupuis^{31,62}, Jose C Florez^{60,114,115,116}, Eric Boerwinkle^{117,118}, James S Pankow¹¹⁹, Cornelia van Duijn^{29,120}, Eric Sijbrands¹⁰⁵, James B Meigs^{114,121}, Frank B Hu^{25,26,27}, Unnur Thorsteinsdottir^{24,41}, Kari Stefansson^{24,41}, Timo A Lakka^{67,122,123}, Rainer Rauramaa^{67,123}, Michael Stumvoll^{43,44}, Nancy L Pedersen¹²⁴, Lars Lind¹²⁵, Sirkka M Keinanen-Kiukaanniemi^{126,127}, Eeva Korpi-Hyövälti¹²⁸, Timo E Saaristo^{129,130}, Juha Saltevo¹³¹, Johanna Kuusisto¹⁰⁰, Markku Laakso¹⁰⁰, Andres Metspalu^{5,132}, Raimund Erbel¹³³, Karl-Heinz Jöckel²², Susanne Moebus²², Samuli Ripatti^{7,21,102,134}, Veikko Salomaa⁵⁵, Erik Ingelsson^{1,23}, Bernhard O Boehm^{135,136}, Richard N Bergman¹³⁷, Francis S Collins⁴⁶, Karen L

Mohlke¹³⁸, Heikki Koistinen^{55,139,140}, Jaakko Tuomilehto^{55,141,142,143}, Kristian Hveem⁷⁰, Inger Njølstad¹⁴⁴, Panagiotis Deloukas^{7,145}, Peter J Donnelly^{1,146}, Timothy M Frayling¹⁰⁶, Andrew T Hattersley¹⁴⁷, Ulf de Faire⁶⁶, Anders Hamsten¹⁶, Thomas Illig^{13,77}, Annette Peters^{14,15,88}, Stephane Cauchi¹², Rob Sladek^{148,149}, Philippe Froguel^{9,12,61}, Torben Hansen^{11,150}, Oluf Pedersen¹¹, Andrew D Morris¹⁵¹, Collin NA Palmer^{52,53}, Sekar Kathiresan^{10, 115,152}, Olle Melander³⁶, Peter M Nilsson³⁶, Leif C Groop^{21,36}, Inês Barroso^{7,153,154}, Claudia Langenberg⁸, Nicholas J Wareham⁸, Christopher A O'Callaghan⁶, Anna L Gloyn^{1,4,92,162}, David Altshuler^{10,112,113,114,155,156,162}, Michael Boehnke^{3,162}, Tanya M Teslovich^{3,162}, Mark I McCarthy^{1,4,92,162}, Andrew P Morris^{1,5,157,158,162}, for the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium¹⁵⁹.

¹Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ²Department of Genetics, Stanford University, Stanford, CA, USA. ³Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ⁴Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. ⁵Estonian Genome Center, University of Tartu, Tartu, Estonia. ⁶Centre for Cellular and Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ⁷Wellcome Trust Sanger Institute, Hinxton, UK. ⁸MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK. ⁹Genomics of Common Disease, Imperial College London, London, UK. ¹⁰Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA. ¹¹The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ¹²Lille Institute of Biology, European Genomics Institute of Diabetes, Lille, France. ¹³Research Unit of Molecular Epidemiology, Helmholtz Zentrum Muenchen, German Research Centre for Environmental Health, Neuherberg, Germany. ¹⁴Institute of Epidemiology II, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Neuherberg, Germany. ¹⁵German Center for Diabetes Research, Neuherberg, Germany. ¹⁶Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. ¹⁷Science for Life Laboratory, Stockholm, Sweden. ¹⁸Department for Numerical Analysis and Computer Science, Stockholm University, Stockholm, Sweden. ¹⁹Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany. ²⁰Medical Systems Biology, Ulm University, Ulm, Germany. ²¹Finnish Institute for Molecular Medicine (FIMM), Helsinki, Finland. ²²Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, Essen, Germany. ²³Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ²⁴deCODE Genetics, Amgen inc., Reykjavik, Iceland. ²⁵Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. ²⁶Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. ²⁷Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ²⁸Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana. ²⁹Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. ³⁰Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ³¹Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ³²Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA. ³³Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³⁴The Genetics of Obesity and Related Metabolic Traits Program, The Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³⁵Perelman School of Medicine, Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA. ³⁶Lund University Diabetes Centre, Department of Clinical Science Malmo, Scania University Hospital, Lund University, Malmo, Sweden. ³⁷Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy. ³⁸Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, Milan, Italy. ³⁹INSERM CESP U1018, Villejuif, France. ⁴⁰University Paris Sud 11, UMRS 1018, Villejuif,

France. ⁴¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ⁴²Landspítali University Hospital, Reykjavik, Iceland. ⁴³IFB Adiposity Diseases, University of Leipzig, Leipzig, Germany. ⁴⁴Department of Medicine, University of Leipzig, Leipzig, Germany. ⁴⁵German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany. ⁴⁶National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. ⁴⁷The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴⁸Endocrinology-Diabetology Unit, Corbeil-Essonnes Hospital, Corbeil-Essonnes, France. ⁴⁹Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ⁵⁰Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ⁵¹Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. ⁵²Diabetes Research Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK. ⁵³Pharmacogenomics Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK. ⁵⁴Lund University Diabetes Centre, Department of Clinical Science Malmö, NovoNordisk Scandinavia AB, Malmö, Sweden. ⁵⁵Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. ⁵⁶Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. ⁵⁷Unit of General Practice, Helsinki University General Hospital, Helsinki, Finland. ⁵⁸Folkhalsan Research Center, Helsinki, Finland. ⁵⁹Division of Endocrinology, Children's Hospital, Boston, MA, USA. ⁶⁰Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA. ⁶¹CNRS-UMR-8199, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France. ⁶²National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA, USA. ⁶³Division of Endocrinology and Metabolism, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁶⁴Department of Clinical Sciences, Lund University, Malmö, Sweden. ⁶⁵Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. ⁶⁶Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁶⁷Kuopio Research Institute of Exercise Medicine, Kuopio, Finland. ⁶⁸Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Dusseldorf, Dusseldorf, Germany. ⁶⁹German Center for Diabetes Research, Partner Site Dusseldorf, Germany. ⁷⁰HUNT Research Center, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway. ⁷¹Cardiovascular Genetics, BHF Laboratories, Institute Cardiovascular Sciences, UCL, London, UK. ⁷²Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, MA, USA. ⁷³Steno Diabetes Center, Gentofte, Denmark. ⁷⁴Research Centre for Prevention and Health, Capital Region of Denmark, Copenhagen, Denmark. ⁷⁵Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁷⁶Faculty of Medicine, University of Aalborg, Aalborg, Denmark. ⁷⁷Hannover Unified Biobank, Hannover Medical School, Hannover, Germany. ⁷⁸Institute of Human Genetics, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Neuherberg, Germany. ⁷⁹Copenhagen University Hospital, Rigshospitalet, Denmark. ⁸⁰Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. ⁸¹Institute of Genetic Epidemiology, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health, Neuherberg, Germany. ⁸²BRC Genomics Core Facility, GSTT Foundation Trust, Guy's & St Thomas' Hospital, London. ⁸³Institute of Human Genetics, University of Bonn, Bonn, Germany. ⁸⁴Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. ⁸⁵Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, D-52425 Jülich, Germany. ⁸⁶Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany. ⁸⁷Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Neuherberg, Germany. ⁸⁸DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. ⁸⁹Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain. ⁹⁰CIBER Epidemiología y Salud Pública (CIBERESP), Spain. ⁹¹Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. ⁹²Oxford National Institute for Health Research Biomedical Research Centre,

Churchill Hospital, Oxford, UK. ⁹³Cancer Research and Prevention Institute (ISPO), Florence, Italy. ⁹⁴Department of Internal Medicine, Levanger Hospital, Nord-Trondelag Health Trust, Levanger, Norway. ⁹⁵Department of Endocrinology and Diabetology, University Hospital Dusseldorf, Dusseldorf, Germany. ⁹⁶Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. ⁹⁷Boston University Data Coordinating Center, Boston, MA, USA. ⁹⁸University Medical Center Utrecht, Utrecht, The Netherlands. ⁹⁹Icelandic Heart Association, Kopavogur, Iceland. ¹⁰⁰Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland. ¹⁰¹Department of Clinical Chemistry and Central Laboratory, University of Ulm, Ulm, Germany. ¹⁰²Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland. ¹⁰³Department of Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland. ¹⁰⁴Research Program for Diabetes and Obesity, University of Helsinki, Helsinki, Finland. ¹⁰⁵Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. ¹⁰⁶Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK. ¹⁰⁷European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, UK. ¹⁰⁸Division of Endocrinology, Germans Trias i Pujol University Hospital and Research Institute, Badalona, Spain. ¹⁰⁹Josep Carreras Leukaemia Research Institute, Badalona, Spain. ¹¹⁰CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. ¹¹¹Department of Medicine, Imperial College London, London, UK. ¹¹²Institut d'Investigacions Biomediques August Pi i Sunyer, Centre Esther Koplowitz, Barcelona, Spain. ¹¹³The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹¹⁴Department of Medicine, Harvard Medical School, Boston, MA, USA. ¹¹⁵Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA. ¹¹⁶Diabetes Research Center, Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA. ¹¹⁷Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA. ¹¹⁸Human Genome Sequencing Center at Baylor College of Medicine, Houston, TX, USA. ¹¹⁹Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA. ¹²⁰Netherlands Genomics Initiative, Netherlands Consortium for Healthy Ageing and Center for Medical Systems Biology, Rotterdam, The Netherlands. ¹²¹General Medicine Division, Massachusetts General Hospital, MA, USA. ¹²²Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio, Finland. ¹²³Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland. ¹²⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ¹²⁵Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. ¹²⁶Faculty of Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland. ¹²⁷Unit of General Practice, Oulu University Hospital, Oulu, Finland. ¹²⁸South Ostrobothnia Central Hospital, Seinäjoki, Finland. ¹²⁹Finnish Diabetes Association, Tampere, Finland. ¹³⁰Pirkanmaa District Hospital, Tampere, Finland. ¹³¹Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland. ¹³²Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. ¹³³Clinic of Cardiology, West German Heart Centre, University Hospital of Essen, University Duisburg-Essen, Essen, Germany. ¹³⁴Public Health Genomics Unit, National Institute for Health and Welfare, Helsinki, Finland. ¹³⁵Division of Endocrinology and Diabetes, Department of Internal Medicine, University Medical Centre Ulm, Ulm, Germany. ¹³⁶Lee Kong Chian School of Medicine, Imperial College London and Nanyang Technological University, Singapore, Singapore. ¹³⁷Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ¹³⁸Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. ¹³⁹Department of Medicine, Division of Endocrinology, Helsinki University Central Hospital, Helsinki, Finland. ¹⁴⁰Minerva Foundation Institute for Medical Research, Helsinki, Finland. ¹⁴¹Instituto de Investigacion Sanitaria del Hospital Universitario LaPaz, Madrid, Spain. ¹⁴²Centre for Vascular Prevention, Danube-University Krems, Krems, Austria. ¹⁴³Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia. ¹⁴⁴Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. ¹⁴⁵William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, UK. ¹⁴⁶Department of Statistics, University of Oxford, Oxford, UK.

¹⁴⁷Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
¹⁴⁸Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de l'Université de
Montreal, Montreal, Canada. ¹⁴⁹McGill University and Centre d'Innovation Génome Québec,
Montreal, Canada. ¹⁵⁰Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
¹⁵¹Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh,
UK. ¹⁵²Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
¹⁵³University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of
Metabolic Science, Cambridge, UK. ¹⁵⁴The National Institute for Health Research Cambridge
Biomedical Research Centre, Cambridge, UK. ¹⁵⁵Department of Genetics, Harvard Medical School,
Boston, MA, USA. ¹⁵⁶Department of Molecular Biology, Harvard Medical School, Boston, MA, USA.
¹⁵⁷Department of Biostatistics, University of Liverpool, Liverpool, UK. ¹⁵⁸Department of Molecular
and Clinical Pharmacology, University of Liverpool, Liverpool, UK. ¹⁵⁹A list of members and
affiliations of the DIAGRAM Consortium appears in the **Supplementary Note**. ¹⁶⁰Deceased. ¹⁶¹These
authors contributed equally to this work. ¹⁶²These authors jointly directed this research.

Correspondence should be addressed to:

K.J.G. (kgaulton@gmail.com)

M.I.M. (mark.mccarthy@drl.ox.ac.uk)

A.P.M. (apmorris@liverpool.ac.uk)

ABSTRACT

We performed fine-mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 57,574 controls of European ancestry. We identified 49 distinct association signals at these loci, including five mapping in/near *KCNQ1*. “Credible sets” of variants most likely to drive each distinct signal mapped predominantly to non-coding sequence, implying that T2D association is mediated through gene regulation. Credible set variants were enriched for overlap with FOXA2 chromatin immunoprecipitation binding sites in human islet and liver cells, including at *MTNR1B*, where fine-mapping implicated rs10830963 as driving T2D association. We confirmed that this T2D-risk allele increases FOXA2-bound enhancer activity in islet- and liver-derived cells. We observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with evidence that the T2D-risk allele increases islet *MTNR1B* expression. Our study demonstrates how integration of genetic and genomic information can define molecular mechanisms through which variants underlying association signals exert their effects on disease.

INTRODUCTION

Genome-wide association studies (GWAS) of common variants, defined by minor allele frequency (MAF) $\geq 5\%$, have been successful in identifying loci contributing to type 2 diabetes (T2D) susceptibility¹⁻⁵. GWAS loci are typically represented by a “lead” SNP with the strongest signal of association in the region. However, lead SNPs may not directly impact disease susceptibility, but instead be proxies for causal variants because of linkage disequilibrium (LD). Interpretation may be further complicated by the presence of more than one causal variant at a locus, possibly acting through the joint effects of alleles on the same haplotype. This complex genetic architecture would result in multiple “distinct” association signals at the same locus, which can only be delineated, statistically, through conditional analyses.

With the exception loci where the lead SNPs are protein altering variants, including *PPARG*⁶, *KCNJ11-ABCC8*⁷, *SLC30A8*⁸, and *GCKR*⁹, the mechanisms by which associated alleles influence T2D susceptibility are largely unknown. At other loci, direct biological interpretation of the effect of genetic variation on T2D is more challenging because the association signals mostly map to non-coding sequence. While recent reports have demonstrated a relationship between T2D-associated variants and transcriptional enhancer activity, particularly in human pancreatic islets, liver cells, adipose tissue, and muscle¹⁰⁻¹⁴, the DNA-binding proteins through which these effects are mediated remain obscure. Localisation of non-coding causal variants may highlight the specific regulatory elements they perturb, and potentially the genes through which they operate, providing valuable insights into the pathophysiological basis of T2D susceptibility at GWAS loci.

To improve the localisation of potential causal variants for T2D, and characterise the mechanisms through which they alter disease risk, we performed comprehensive fine-mapping of 39 established loci through high-density imputation into 27,206 cases and 57,574 controls from 23 studies of European ancestry, genotyped with the MetaboChip¹⁵ (**Supplementary Tables 1 and 2**). Within each locus, we aimed to: (i) evaluate the evidence for multiple distinct association signals through conditional analyses; (ii) undertake fine-mapping by defining credible sets of variants that account for $\geq 99\%$ of the probability of driving each distinct association signal; and (iii) interrogate credible sets for functional and regulatory annotation to provide insight into the mechanisms through which variants driving association signals influence disease risk.

RESULTS

Imputation into MetaboChip fine-mapping regions

The MetaboChip includes high-density coverage of 257 “fine-mapping regions” that have been previously associated with 23 metabolic, cardiovascular, and anthropometric traits¹⁵. SNPs in these regions were selected using reference data from the HapMap¹⁶ and the 1000 Genomes (1000G) Project¹⁷. At design, 27 T2D susceptibility loci were selected for fine-mapping. However, subsequent T2D GWAS efforts have identified additional loci that overlap 12 further fine-mapping regions that were initially selected for other traits (**Supplementary Table 3**). To enhance coverage of variation in the fine-mapping regions, we undertook imputation into the MetaboChip scaffold up to the 1000G phase 1 integrated

reference panel (March 2012 release)¹⁸, including multi-ethnic haplotypes to reduce error rates¹⁹ (**Online Methods**).

The quality of imputation was variable across studies, particularly for MAF<5% variants, and dependent on the scaffold sample size (**Supplementary Table 4**). We defined variants to be “well-imputed” at widely-used thresholds²⁰ of IMPUTEv2²¹ info \geq 0.4 or minimac²² $r^2\geq$ 0.3 in at least 80% of the total effective sample size ($N_{\text{eff}}\geq$ 59,122) across studies. With this definition, 99.4% and 89.0%, respectively, of common and low-frequency ($0.5\%\leq$ MAF<5%) variants in 1000G European ancestry haplotypes were well imputed, and therefore retained for downstream association analyses. Within studies, imputation quality was consistent across loci, despite the differential priority of fine-mapping regions and their coverage of variation at design (**Supplementary Table 5**). 1000G imputation into the Metachip scaffold thus provides near complete coverage of common and low-frequency variation across the 39 T2D susceptibility loci, and supports direct interrogation of the majority of variants with MAF \geq 0.5% in European ancestry populations.

Distinct association signals at T2D susceptibility loci

The first step in fine-mapping GWAS loci is to delineate distinct association signals arising from multiple causal variants in the same region, which can efficiently be achieved through approximate conditioning with GCTA²³. Within each T2D fine-mapping region, we identified distinct signals attaining “locus-wide” significance (represented by an index variant with $p_j<10^{-5}$ in the joint association model) by applying GCTA in two stages (**Online Methods**). First, we selected index variants on the basis of fixed-effects meta-analysis across Metachip studies. Second, we performed *in silico* replication of the index variants in a validation meta-analysis of an additional 19,662 T2D cases and 115,140 controls from 10 GWAS of European ancestry (**Supplementary Tables 1, 2, and 6**). Finally, because GCTA is only an approximation, we confirmed the association of each index variant through exact conditional analysis across Metachip studies (**Online Methods, Supplementary Table 7**).

The most dramatic delineation of distinct association signals was observed for the region flanking *KCNQ1*, where five non-coding index variants attained locus-wide significance (**Table 1, Supplementary Figure 1**). Distinct association signals represented by three of the index variants have been reported in previous GWAS of European⁴ and East Asian²⁴ ancestry: rs74046911 ($p_j=3.6\times 10^{-26}$, $r^2=0.98$ with East Asian lead SNP, rs2237897) and rs2237895 ($p_j=2.1\times 10^{-9}$, $r^2=0.75$ with one European lead SNP, rs163184), both of which map to a <50kb intronic recombination interval of *KCNQ1*; and chr11:2692322:D ($p_j=7.2\times 10^{-16}$, $r^2=0.59$ with second European lead SNP, rs231361), which resides in the *KCNQ1OT1* transcript that controls regional imprinting²⁵. The remaining two distinct association signals at this locus are novel. The first, indexed by rs458069 ($p_j=3.2\times 10^{-6}$), maps to the same <50kb recombination interval as rs74046911 and rs2237895, but is in only weak LD with both ($r^2=0.02$ and $r^2=0.25$, respectively). The second, indexed by rs2283220 ($p_j=2.2\times 10^{-7}$), resides in a neighbouring intron of *KCNQ1*, outside of the <50kb recombination interval (**Supplementary Figure 1**).

At the *HNF1A* locus, we observed three distinct association signals (**Table 1, Supplementary Figure 2**), represented by index variants that are in only weak LD with the previously reported lead GWAS SNP, rs12427353. They include two non-synonymous variants, rs1169288 ($p_j=4.4\times 10^{-14}$, $r^2=0.09$, *HNF1A* p.I27L) and rs1800574 ($p_j=4.2\times 10^{-10}$, $r^2=0.01$, *HNF1A* p.A98V), and one inter-genic SNP, chr12:121440833:D ($p_j=2.9\times 10^{-10}$, $r^2=0.19$).

We also observed four loci with two distinct association signals (*CDKN2A-B*, *DGKB*, *MC4R* and *GIPR*), each represented by non-coding index variants (**Table 1, Supplementary Figure 3**). The index variants at the *CDKN2A-B* locus represent the known T2D haplotype association signal mapping to a 12kb inter-genic recombination interval²⁶⁻²⁸. Previous European ancestry GWAS meta-analyses⁴ have highlighted a potential distinct association signal, located upstream of the recombination interval in the non-coding *CDKN2B-AS1* (*ANRIL*) transcript. However, our conditional analyses indicate that the association in this region can be fully explained by the two index SNPs in the recombination interval, which when considered together, fully extinguish the *CDKN2B-AS1* signal (**Supplementary Figure 4**). The index variants at *DGKB* and *MC4R* also confirm previously reported distinct association signals at these loci in European ancestry GWAS meta-analyses⁴. At the *GIPR* locus, the two index variants (*rs2238689*, $p_j=8.3 \times 10^{-16}$; *rs4399645*, $p_j=1.4 \times 10^{-8}$) are not in strong LD with the previously reported⁴ lead SNP (*rs8108269*; $r^2=0.43$ with *rs2238689*, $r^2=0.00$ with *rs4399645*), but together can better explain the T2D association signal in this region.

Finally, we observed a novel distinct association signal at the *HNF4A* locus, represented by the coding index variant *rs1800961* ($p_j=1.4 \times 10^{-9}$, *HNF4A* p.T139I, referred to as p.T130I in some previous studies²⁹). Unfortunately, this fine-mapping region was included on MetaboChip for high-density lipoprotein cholesterol^{15,30} (**Supplementary Table 3**), and does not include the previously reported⁴ lead T2D SNP at this locus, *rs4812829*, precluding conditional analyses in these data. However, *rs4812829* is not in LD with our index variant ($r^2=0.02$), suggesting that there are at least two distinct T2D association signals at the *HNF4A* locus.

Of the 49 distinct association signals achieving locus-wide significance across T2D loci represented on MetaboChip (five at *KCNQ1*, three at *HNF1A*, two each at *CDKN2A-B*, *DGKB*, *MC4R* and *GIPR*, and one each at the remainder), only three index variants are not common (**Supplementary Table 6, Supplementary Figure 5**): *rs1800574* (MAF=2.2%, OR=1.21) for one signal at the *HNF1A* locus; *rs1800961* (MAF=3.9%, OR=1.16) at the *HNF4A* locus; and *rs17066842* (MAF=4.8%, OR=1.12) for one signal at the *MC4R* locus.

Localising variants driving T2D association signals

We used statistical evidence of association from the meta-analysis of MetaboChip studies to construct 99% “credible sets” of variants²⁸ that are most likely to drive the 49 distinct signals (**Online Methods, Supplementary Table 8, Supplementary Figure 6**). For ten distinct association signals, mapping to nine loci, the 99% credible set included no more than ten variants (**Table 2, Supplementary Table 9**). The greatest refinement was observed at the *MTNR1B* locus, where the credible set included only the index variant, *rs10830963*, accounting for more than 99.8% of the posterior probability of driving the association signal (π_c). Small credible sets were also observed for the association at *TCF7L2* (three variants, indexed by *rs7903146*, mapping to 4.3kb), and one signal at *KCNQ1* (three variants, indexed by *rs74046911*, mapping to just 200bp). The 99% credible sets for both distinct association signals at *CDKN2A-B* together included just 11 variants in total, and map to less than 2kb.

We performed functional annotation of credible variants to search for evidence that association signals are driven by coding alleles. Across the 49 signals, only nine coding variants attained $\pi_c > 1\%$ (**Supplementary Table 10**), including six previously reported non-synonymous T2D-risk alleles at *PPARG*⁶, *KCNJ11-ABCC8*^{7,31,32}, *SLC30A8*^{8,33}, and *GCKR*^{9,34}. The

remaining three coding alleles were the index variants for association signals mapping to *HNF4A* (p.T139I, rs1800961, $\pi_c=97.4\%$) and *HNF1A* (p.I27L, rs1169288, $\pi_c=75.5\%$; p.A98V, rs1800574, $\pi_c=34.0\%$). Our findings are supported by earlier studies, which reported nominal evidence for association of these three coding variants with T2D and defects in insulin secretion *in vivo*, and demonstrated reduced transcriptional activity of *HNF1A* target genes using *in vitro* assays^{29,35}. These data provide strong evidence that *HNF4A* and *HNF1A* are T2D effector transcripts at these loci, a view further supported by the known impact of rare, loss of function mutations in these genes on maturity onset diabetes of the young^{36,37}. Given the near complete coverage of common and low-frequency variants in fine-mapping regions after 1000G imputation, it is unlikely that additional distinct signals in established T2D susceptibility loci represented on the MetaboChip are driven by coding variation with $MAF \geq 0.5\%$, confirming reports that these associations are most likely to be mediated by effects on gene regulation^{10,13,14,38}.

Regulatory mechanisms underlying T2D association signals

We sought to understand the regulatory mechanisms through which variants at the 39 established T2D susceptibility loci influence disease by intersecting the 99% credible sets for each distinct association signal with chromatin immunoprecipitation sequence (ChIP-seq) data for 165 transcription factors, chromatin state maps from 12 cell types, and long non-coding RNA transcripts from 25 cell types (**Online Methods, Supplementary Table 11**). We applied an enrichment procedure that compared the mean posterior probability of driving the association signal for credible set variants directly overlapping sites for each regulatory annotation with a null distribution obtained from randomly shifted site locations within 100kb in either direction.

We first applied this procedure to chromatin state and non-coding RNA elements using the 19,266 credible set variants for all 49 distinct association signals (**Supplementary Figure 7**). Using a Bonferroni correction for the 37 tested cell type annotations ($p < 0.0014$), variants in pancreatic islet enhancer elements¹⁴ had significantly higher posterior probability of driving association signals than that expected from the null distribution (1.97-fold, $p = 0.00022$). We also observed nominal evidence for enrichment of the posterior probability of driving association signals among variants in human islet and hepatocellular carcinoma (HepG2) promoters^{10,14} ($p = 0.0052$ and $p = 0.0064$, respectively). However, there was no corresponding enrichment of variants in regulatory elements for other cell types or in non-coding transcripts. These results are consistent with previous studies supporting a contribution of regulatory enhancer and promoter variants to T2D susceptibility in specific cell types¹¹⁻¹⁴.

We next sought to gain insight into the transcription factors these regulatory variants perturb, and applied the same procedure to ChIP-seq binding data for 165 proteins (**Figure 1, Supplementary Figure 8**). Using a Bonferroni correction for the 165 tested proteins ($p < 0.00030$), the 89 credible set variants overlapping 57 FOXA2 ChIP-seq binding sites, assayed in human HepG2¹⁰ and islet¹⁴ cells, had significantly higher posterior probability of driving association signals than expected from the null distribution (8.24-fold, $p = 0.00028$). The enrichment of FOXA2 ChIP-seq sites was exclusive to those shared with at least one other factor (9.18-fold, $p = 0.00028$) compared to those that were not (1.12-fold, $p = 0.11$). FOXA2 enrichment was also more pronounced among sites identified in pancreatic islets (15.43-fold, $p = 0.00045$) than in HepG2 cells (4.55-fold, $p = 0.011$). To exclude the

possibility that this enrichment in HepG2 cells was driven by artefacts caused by a cultured cell line, we compared FOXA2 HepG2 sites to those previously assayed in primary liver³⁹. We observed significant intersection of the HepG2 and liver FOXA2 sites that overlapped credible set variants ($p=1.5\times 10^{-9}$). Consequently, we detected similar FOXA2 enrichment among sites detected in liver (3.63-fold, $p=0.061$) to that observed in HepG2 cells. We also compared FOXA2 ChIP-seq sites, genome-wide, from liver, HepG2 and islet cells (**Supplementary Figure 9**). The number of sites varied across cell types (8,023 for liver, 40,866 for HepG2, and 27,291 for islets), which is likely due, in part, to technical differences including sequencing platform, depth and read length. However, the intersection of FOXA2 sites between each pair of cell types was highly significant ($p<2.2\times 10^{-16}$).

Given the preponderance of T2D-associated variants for islet enhancers, we next tested to what extent FOXA2 enrichment is driven by co-localisation with these genomic features¹⁴. Variants in FOXA2-bound sites were not enriched for posterior probability of driving association signals after removing enhancer sites (0.36-fold, $p=0.69$). Conversely, variants in islet enhancers remained nominally enriched when removing FOXA2 sites (1.65-fold, $p=0.014$). These results suggest that FOXA2 binding assayed by ChIP-seq, at a subset of enhancer element locations that are often shared by other proteins, is a genomic marker of variants with an increased posterior probability of driving T2D association signals.

Having demonstrated global over-representation for FOXA2 ChIP-seq binding by considering all loci simultaneously, we applied the same procedure to the 99% credible sets of each distinct association signal, separately, to identify those with the strongest evidence for local enrichment (**Figure 1**). We observed over-representation of credible set variants in islet or HepG2 FOXA2 sites for 19 association signals, 15 of which attained nominal significance ($p<0.05$). A total of 41 credible set variants at these 19 distinct association signals overlap a FOXA2 ChIP-seq site in at least one of the two cell types (**Supplementary Table 12**). Of these, 12 variants were predicted to disrupt *de novo* recognition motifs (for FOXA2 and other factors) that were enriched in FOXA2-bound sequence (**Table 3**, **Supplementary Table 13**). The mean posterior probability of driving the association (π_c) for these 12 variants was 22.0% on the basis of genetic fine-mapping (**Figure 1**), more than four times greater than for those in FOXA2 ChIP-seq sites that were not motif-disrupting at the same signals (mean π_c of 5.2%, $p=0.024$). Furthermore, 11 of these 12 variants also overlapped an enhancer element in islets (9 variants) or HepG2 cells (6 variants), indicating that they are in transcriptionally active regions (**Table 3**). They include two variants with experimentally validated differences in regulatory activity: rs7903146 ($\pi_c=77.6\%$) at *TCF7L2*⁴⁰ and rs11257655 ($\pi_c=21.1\%$) at *CDC123*⁴¹. They also include rs10830963, the index variant at the *MTNR1B* locus, which accounts for 99.8% of the posterior probability of driving the association signal on the basis of genetic fine-mapping. These results suggest that FOXA2 binding patterns can be used to highlight specific variants that are potentially causal for T2D susceptibility through altered regulatory binding.

Altered regulatory activity of the *MTNR1B* credible variant

To demonstrate how local enrichment of FOXA2 binding can be used to highlight regulatory mechanisms through which credible variants might impact T2D susceptibility, we focussed on the *MTNR1B* locus. Variants mapping to this region have amongst the strongest known effects on both T2D risk⁶ and fasting plasma glucose concentration⁴², and physiological data indicate an impact of *MTNR1B* on both insulin secretion and insulin action⁴³. The lone

credible variant at *MTNR1B*, rs10830963, overlaps a FOXA2 ChIP-seq binding site, and the risk allele, G, is predicted to create a recognition motif that matches the consensus sequence of NEUROD1 and several other factors (**Figure 2, Supplementary Table 13**). We tested *in silico* predictions of protein binding at rs10830963 via electrophoretic mobility shift assay (EMSA) with 25bp probe fragments surrounding each allele in human pancreatic islet beta-cell (EndoC-βH1)⁴⁴ or human liver HepG2 cell extracts. We observed allele-specific binding with extracts from both cell lines (**Figure 2, Supplementary Figure 10**).

To determine the specific protein(s) bound at each allele, we then performed supershift experiments using antibodies directed against NEUROD1, FOXA2, and three other factors (TAL1, PTF1A, and YY1), whose consensus binding sequences resemble the recognition motif (**Online Methods**). We observed a shift in the presence of the NEUROD1 antibody on the risk allele in EndoC-βH1 extracts, which could be competed away by an excess of unlabelled NEUROD1 consensus sequence probe (**Figure 2**). None of the tested antibodies (including NEUROD1) shifted the risk allele band in HepG2 cell extracts (**Supplementary Figure 10**). These results demonstrate that, *in vitro*, the risk allele of rs10830963 preferentially binds NEUROD1 in islet-derived cells, and binds a protein not identified from known recognition motifs in liver-derived cells.

To relate allelic differences in protein binding to genomic activity at this site, we cloned a 224bp region surrounding rs10830963 into a luciferase reporter vector containing a minimal promoter, and tested its enhancer activity in EndoC-βH1 and HepG2 cell lines. Consistent with *in silico* predictions, we observed a significant ($p < 0.05$) increase in luciferase expression on the risk allele compared to the protective allele in both cell lines (**Figure 2**). Furthermore, RNA-seq data reported from human islets have linked the T2D risk allele of rs10830963 to increased expression of *MTNR1B*^{45,46}. Taken together, these results suggest that the G allele of rs10830963 increases T2D risk through increased FOXA2-bound enhancer activity, potentially mediated through NEUROD1 binding in islets, and consequently higher expression of *MTNR1B*.

Candidate effector genes at FOXA2 enriched T2D signals

We hypothesised that the locus-specific effects of murine transcription factor knockout models would mimic patterns of binding enrichment at human disease loci. We thus attempted to relate FOXA2 binding at the 19 FOXA2-enriched association signals (**Figure 1**) to target effector genes using previously reported pancreatic islet expression profiles from wild-type and *Foxa1/2*-null mice⁴⁷ (**Online Methods**). Syntenic genes mapping within 500kb of the credible set at the 19 FOXA2-enriched signals were significantly down-regulated (45.2% decrease) in *Foxa1/2* knockout mice (**Supplementary Figure 11**) compared to those genome-wide (0.021% increase, $p = 0.012$), whilst those mapping within 500kb of the other 30 T2D association signals were not (2.25% decrease, $p = 0.20$). We observed a consistent down-regulation (39.6% decrease) when considering only those genes mapping closest to each FOXA2-enriched signal, compared to those genome-wide (0.021% increase, $p = 0.0021$). Thus, data related to altered gene expression in *Foxa1/2* knockout mice support patterns of FOXA2 binding site enrichment in humans.

We next identified specific genes at the 19 FOXA2-enriched association signals that were down-regulated in *Foxa1/2* knockout mice, which might represent effector transcripts for these loci (**Supplementary Table 14**). Several of these genes have been previously implicated as likely effector transcripts in humans, including *TCF7L2*^{48,49} (57% decrease),

KCNJ11^{7,50} (38% decrease), and *SLC30A8*⁵¹ (135% decrease). These data also implicate novel candidate effector genes at FOXA2-enriched association signals (**Supplementary Table 14**). For example, in *Foxa1/2* knockout mice, there is a marked down-regulation of *Reg4* (1,415% decrease), which maps to a syntenic region at the FOXA2-enriched *NOTCH2* GWAS locus, highlighting *REG4* as a likely effector transcript in humans. Additional examples of candidate effector genes include *IGF2* at the *KCNQ1* locus (135% decrease), and *CAMK1D* at the *CDC123* locus (81% decrease). Together, these results provide additional support for the importance of FOXA2 binding at a subset of T2D susceptibility loci, and further highlight specific genes through which regulatory variants in these regions may operate.

DISCUSSION

We have undertaken comprehensive fine-mapping of 39 established T2D susceptibility loci in 27,206 cases and 57,574 controls of European ancestry, and have demonstrated that multiple distinct association signals in these regions is a common phenomenon. Index variants for just three of the 49 distinct association signals are not common, despite near complete coverage of variation with $MAF \geq 0.5\%$ in fine-mapping regions after 1000G imputation. Although we cannot evaluate the impact of rare variation ($MAF < 0.5\%$) in established T2D susceptibility loci without large-scale re-sequencing, our data strongly argue against a role for low-frequency variants of large effect via synthetic association⁵². We have demonstrated that seven distinct association signals, mapping to six T2D susceptibility loci represented on the Metachip, are likely to be driven by coding alleles, including novel index variants mapping to *HNF1A* and *HNF4A*. Outside of these regions, our fine-mapping confirms previous reports that T2D association signals are primarily driven by non-coding alleles, with effects that are mediated through gene regulation^{10,13,14,38}.

We have demonstrated, by genomic annotation and functional assays, that FOXA2 binding assayed by ChIP-seq can be used to pinpoint candidate causal regulatory elements, providing routes to understanding the biology of specific T2D susceptibility loci. These elements highlight variants and effector transcripts through which association signals are mediated, via altered binding of either FOXA2, directly, or another transcription factor. For example, at the *MTNR1B* locus, the risk allele of the lone credible variant, rs10830963, which drives the T2D association signal, preferentially binds NEUROD1 in islet-derived cells *in vitro*, and increases FOXA2-bound enhancer activity in human islet and liver-derived cells. These data are consistent with previous reports correlating the risk allele with higher *MTNR1B* expression^{45,46}, and not loss of function⁵³, and suggest altered NEUROD1 binding in islets contributes to T2D susceptibility at this locus. Further experiments will be required to establish that our *in vitro* findings regarding NEUROD1 binding can be confirmed *in vivo*. However, our attempts to perform ChIP-Seq in primary islet samples of the defined *MTNR1B* genotype were repeatedly unsuccessful, owing to a lack of a suitable NEUROD1 antibody. These studies are further complicated by the limited availability of primary human islets, and the slow division rate of human islet derived cell-lines is an impediment to the implementation of genome-editing technologies.

FOXA2 is a pioneer factor that binds native chromatin and bookmarks genomic regions for transcriptional activity⁵⁴, and is involved in pancreatic and hepatic development^{55,56}. FOXA2 is also expressed in other T2D-relevant cell types, such as adipocytes. Future studies will be required to elucidate the extent to which FOXA2 binding events across cell types influence disease risk. *Foxa2* null mice have impaired insulin

secretion⁴⁷, and common variants at the *FOXA2* locus are associated with fasting plasma glucose concentrations^{42,57}. Our findings are thus consistent with the involvement of *FOXA2* in maintaining normal glucose homeostasis. Common T2D-associated variants at *FOXA2* have also been reported in South Asians⁵⁸, although they do not attain genome-wide significance in the largest GWAS for the disease from multiple ancestry groups¹⁻⁵, and therefore require further replication. Enrichment of *FOXA2* binding has also been reported within genomic intervals containing GWAS signals for endocrine, neuropsychiatric, cardiovascular and cancer traits⁵⁹. Our study has the advantage that we consider only those *FOXA2* sites that directly overlap variants that drive association signals by first fine-mapping GWAS loci, thereby providing more targeted credible sets for functional enrichment. Nevertheless, the results of these studies, taken together, suggest a possible role for *FOXA2* across a broad spectrum of complex human phenotypes.

In conclusion, we have highlighted that *FOXA2* binding patterns can be used to inform future hypothesis-driven investigation of the variants, genes, and molecular mechanisms underlying T2D association signals mapping to non-coding sequence. Continued identification of the effector transcripts at these non-coding association signals will require the use of expression QTL and knockout models, in combination with high-throughput experimental data derived from chromatin conformation capture techniques, such as Capture-C. Our findings support the use of transcription factor binding events as a means to partition susceptibility loci, potentially residing in distinct pathways, within disease-relevant cell types. Finally, our study demonstrates the utility of fine-mapping through integration of genetic and genomic information from relevant tissues and cellular models to elucidate the pathophysiology of complex human diseases, thus offering a promising avenue for translation of GWAS findings for clinical utility.

URLs

Endocells (www.endocells.com)

ACKNOWLEDGEMENTS

Funding for the research undertaken in this study has been received from: Academy of Finland (including grant numbers 77299, 102318, 10493, 118065, 123885, 124243, 129293, 129680, 136895, 139635, 211119, 213506, 251217, and 263836); Agence National de la Recherche; Association de Langue Francaise pour l'Etude du Diabete et des Maladies Metaboliques; Association Diabete Risque Vasculaire; Association Francaise des Diabetiques; Association of Danish Pharmacies; Augustinus Foundation; Becket Foundation; British Diabetes Association (BDA) Research; British Heart Foundation; Central Norway Health Authority; Central Finland Hospital District; Center for Inherited Disease Research (CIDR); City of Kuopio; City of Leutkirch; Copenhagen County; the Danish Centre for Evaluation and Health Technology Assessment; Danish Council for Independent Research; Danish Heart Foundation; Danish Research Councils; Deutsche Forschungsgemeinschaft (including project ER 155/6-2); the Diabetes Research Foundation; Diabetes UK; Doris Duke Charitable Foundation; Erasmus Medical Center; Erasmus University; Estonian Government (SF0180142s08); European Commission (including ENGAGE HEALTH-F4-2007-201413, FP7-201413, FP7-245536, EXGENESIS LSHM-CT-2004-005272, FP6 LSHM_CT_2006_037197, LSHM-CT-2007-037273, Directorate C-Public Health 2004310, DG XII); European Regional Development Fund; Federal Ministry of Education and Research, Germany (including FKZ 01GI1128 and FKZ 01EO1001); Federal Ministry of Health, Germany; Finnish Diabetes Association; Finnish Diabetes Research Foundation; Finnish Foundation for Cardiovascular Research; Finnish Medical Society; Folkhalsan Research Foundation; Foundation for Life and Health in Finland; Foundation for Old Servants; Fredrick och Ingrid Thuring Foundation; French Region of Nord Pas de Calais (Contrat de Projets Etat-Region); German Center for Diabetes Research; German Research Council (including grant number GRK1041); German National Genome Research Network; Groupe d'Etude des Maladies Metaboliques et Systemiques; Health Care Centers in Vasa, Narpes and Korsholm; the Health Foundation; Heinz Nixdorf Foundation; Helmholtz Zentrum Munchen; Helsinki University Central Hospital Research Foundation; Hospital District of Southwest Finland; Ib Henriksens Foundation; IngaBritt and Arne Lundberg's Research Foundation (including grant number 359); Karolinska Institutet; Knut and Alice Wallenberg Foundation (including grant number KAW 2009.0243); Kuopio University Hospital; Lundbeck Foundation; Magnus Bergvall Foundation; Medical Faculty of the University Duisburg-Essen; Medical Research Council, UK (including grant numbers G0000649 and G0601261); Ministry for Health, Welfare and Sports, Netherlands; Ministry of Education and Culture, Finland (including grant number 722 and 627;2004-2011); Ministry of Education, Culture and Science, Netherlands; Ministry of Health and Prevention, Denmark; Ministry of Social Affairs and Health, Finland; Ministry of Innovation, Science, Research and Technology of North Rhine-Westphalia, Germany; Munich Center of Health Sciences; Municipal Health Care Center and Hospital in Jakobstad; Municipality of Rotterdam; Narpes Health Care Foundation; National Health Screening Service of Norway; National Heart, Lung, and Blood Institute, USA (including grant numbers/contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C,

HHSN268201100012C, N01HC25195, N02HL64278, R01HL087641, R01HL59367, and R01HL086694); National Human Genome Research Initiative, USA (including grant numbers/contracts U01HG004402 and N01HG65403); National Institute for Diabetes and Digestive and Kidney Diseases, USA (including grant numbers R01-DK078616, U01-DK085526, K24-DK080140, and R01-DK073490); National Institute for Health and Welfare, Finland; National Institutes of Health, USA (including grant numbers/contracts HHSN268200625226C, UL1RR025005, R01DK062370, R01DK072193, 1Z01HG000024, AG028555, AG08724, AG04563, AG10175, AG08861, U01HG004399, DK58845, CA055075, DK085545, and DK098032); Netherlands Genomics Initiative; Netherlands Organisation for the Health Research and Development; Netherlands Organisation of Scientific Research NOW Investments (including numbers 175.010.2005.011, 911-03-012, 050-060-810); Nord-Trondelag County Council; Nordic Center of Excellence in Disease Genetics; Norwegian Institute of Public Health; Norwegian Research Council; Novo Nordisk Foundation; Ollquist Foundation; Oxford NIHR Biomedical Research Centre; Paavo Nurmi Foundation; Paivikki and Sakari Sohlberg Foundation; Perklen Foundation; Pirkanmaa Hospital District, Finland; Programme Hospitalier de Recherche Clinique; Programme National de Recherche sur la Diabete; Research Institute for Diseases in the Elderly (including grant number 014-93-015); Robert Dawson Evans Endowment, Department of Medicine, Boston University School of Medicine and Boston Medical Center; Royal Swedish Academy of Sciences; Sarstedt AG & Co., Germany; Signe and Ane Gyllenberg Foundation; Sigrid Juselius Foundation; Slottery Machine Association, Finland; Social Insurance Institution of Finland; South OstroBothnia Hospital District; State of Baden-Wuerttemberg, Germany; Stockholm County Council (including grant number 560183); Swedish Cultural Foundation, Finland; Swedish Diabetes Foundation; Swedish e-science Research Center ; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation; Swedish Research Council (including grant numbers SFO EXODIAB 2009-1039, 521-2010-3490, 521-2007-4037, 521-2008-2974, ANDIS 825-2010-5983, LUDC 349-2008-6589, and 8691); Swedish Society of Medicine; Tore Nilsson Foundation; Torsten and Ragnar Soderbergs Stiftelser (including grant number MT33/09); University Hospital Essen; University of Tromso; UCL NIHR Biomedical Research Centre; UK NIHR Cambridge Biomedical Research Centre; Uppsala University; Uppsala University Hospital; Vaasa Hospital District; Velux Foundation; Wellcome Trust (including the Biomedical Collections Grant GR072960, and grant numbers 076113, 083948, 090367, 090532, 083270, 086596, 098017, 095101, 098051, 098381). The authors are grateful to Raphael Scharfmann (INSERM U1016, Cochin Institute Paris) for the gift of EndoC BH-1 cells and for providing technical support with their maintenance. The authors thank Paul Johnson and the Oxford National Institute for Health Research Biomedical Research Centre funded Islet Isolation facility for providing human islets for this study. Detailed acknowledgements are provided in the **Supplementary Note**.

AUTHOR CONTRIBUTIONS

Writing group. K.J.G., T.F., Y.Lee, A.R., R.M., M.Reschen, A.L.G., D.A., M.Boehnke, T.M.T., M.I.M., A.P.M.

Central meta-analysis group. K.J.G., T.F., Y.Lee, R.M., A.Mahajan, A.Locke, N.W.R., N.R., T.M.T., M.I.M., A.P.M.

Annotation and functional analysis group. K.J.G., A.R., M.Reschen, S.K.T., J.K.R., N.L.B., M.v.d.B., A.C., I.D., E.Birney, L.Pasquali, J.Ferrer, C.A.O'C., A.L.G., M.I.M.

Validation meta-analysis group. R.M., R.A.S., I.P., L.J.S., A.P.M.

Metabohip cohort-level primary analysis. Y.Lee, T.G., T.S., D.T., L.Y., H.G., S.Wahl, M.F., R.J.S., H.Kestler, H.Chheda, L.E., S.G., T.M.T., A.P.M.

Validation cohort-level primary analysis. V.Steinthorsdottir, G.T., L.Q., L.C.K., E.v.L., S.M.W., M.Li, H.Chen, C.Fuchsberger, P.Kwan, C.M., M.Linderman, Y.Lu

Metabohip design. H.M.K., B.F.V.

Cohort sample collection, genotyping, phenotyping, or additional analysis. B.F.V., G.R.A., P.A., D.B., B.B., R.B., M.Blüher, H.B., L.L.B., E.P.B., N.B., J.C., G.C., P.S.C., M.C.C., D.J.C., A.T.C., R.M.v.D., A.S.F.D., M.D., S.E., J.G.E., T.E., E.E., J.Fadista, J.Flannick, P.Fontanillas, C.Fox, P.W.F., K.G., C.G., B.G., O.G., G.B.G., N.G., C.J.G., M.H., C.T.H., C.H., O.L.H., A.B.H., S.E.H., D.J.H., A.U.J., A.J., M.E.J., T.J., W.H.L.K, N.D.K., L.K., N.K., A.K., P.Kovacs, P.Kraft, J.Kravic, C.Langford, K.L., L.Liang, P.L., C.M.L., E.L., A.Linneberg, C.-T.L., S.L., J.L., V.L., S. Männistö, O.McLeod, J.M., E.M., G.M., T.W.M., M.M.-N., C.N., M.M.N., N.N.O., K.R.O., D.P., S.P., L.Peltonen, J.R.B.P., C.G.P.P., M.Roden, D.Ruderfer, D.Rybin., Y.T.v.d.S., B.S., G.Sigurðsson, A.S., G.Steinbach, P.S., K.Strauch, H.M.S., Q.S., B.T., E.Tikkanen, A.T., J.Trakalo, E.Tremoli, T.T., R.W., S.Wiltshire, A.R.W., E.Z.

Validation cohort principal investigators. R.L., J.D., J.C.F., E.Boerwinkle, J.S.P., C.v.D., E.S., J.B.M., F.B.H., U.T., K.Stefansson, P.D., P.J.D., T.M.F., A.T.H., I.B., C.Langenberg, N.J.W., M.Boehnke, M.I.M.

Metabohip cohort principal investigators. T.A.L., R.R., M.S., N.L.P., L.Lind, S.K.-K., E.K.-H., T.E.S., J.S., J.Kuusisto, M.Laakso, A.Metspalu, R.E., K.-H.J., S.Moebus, S.R., V.Salomaa, E.I., B.O.B., R.N.B., F.S.C., K.L.M., H.Koistinen, J.Tuomilehto, K.H., I.N., P.D., P.J.D., T.M.F., A.T.H., U.d.F., A.H., T.I., A.P., S.C., R.S., P.Froguel, O.P., T.H., A.D.M., C.N.A.P., S.K., O.Melander, P.M.N., L.C.G., I.B., C.Langenberg, N.J.W., D.A., M.Boehnke, M.I.M.

Project management. K.J.G., A.L.G., D.A., M.Boehnke, T.M.T., M.I.M., A.P.M.

DIAGRAM Consortium management. D.A., M.Boehnke, M.I.M.

1. Kooner, J.S. *et al.* Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. *Nat. Genet.* **43**, 984-989 (2011).
2. Cho, Y.S. *et al.* Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in East Asians. *Nat. Genet.* **44**, 67-72 (2012).
3. Voight, B.F. *et al.* Twelve type 2 diabetes susceptibility loci identified through large scale association analysis. *Nat. Genet.* **42**, 579-589 (2010).
4. Morris, A.P. *et al.* Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat. Genet.* **44**, 981-990 (2012).
5. Mahajan, A. *et al.* Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat. Genet.* **46**, 234-244 (2014).
6. Altshuler, D. *et al.* The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat. Genet.* **26**, 76-80 (2000).
7. Gloyn, A.L. *et al.* Large-scale association studies of variants in genes encoding the pancreatic-cell KATP channel subunits Kir6.2 (*KCNJ11*) and SUR1 (*ABCC8*) confirm that the *KCNJ11* E23K variant is associated with type 2 diabetes. *Diabetes* **52**, 568-572 (2003).
8. Sladek, R. *et al.* A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* **445**, 881-885 (2007).
9. Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes. *Nat. Genet.* **42**, 105-116 (2010).
10. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57-74 (2012).
11. Elbein, S.C., Gamazon, E.R., Das, S.K., Rasouli, N., Kern, P.A. & Cox, N.J. Genetic risk factors for type 2 diabetes: a trans-regulatory genetic architecture? *Am. J. Hum. Genet.* **91**, 466-477 (2012).
12. Trynka, G. *et al.* Chromatin marks identify critical cell types for fine-mapping complex trait variants. *Nat. Genet.* **45**, 124-130 (2013).
13. Parker, S.C.J. *et al.* Chromatin stretch enhancer states drive cell-specific gene regulation and harbour human disease risk variants. *Proc. Natl. Acad. Sci. USA* **110**, 17921-17926 (2013).
14. Pasquali, L. *et al.* Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. *Nat. Genet.* **46**, 136-143 (2014).
15. Voight, B.F. *et al.* The Metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. *PLoS Genet.* **8**, e1002793 (2012).
16. International HapMap Project Consortium. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851-861 (2007).
17. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061-1073 (2010).
18. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56-65 (2012).
19. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat. Rev. Genet.* **11**, 499-511 (2010).

20. Winkler, T.W. *et al.* Quality control and conduct of genome-wide association meta-analyses. *Nat. Protoc.* **9**, 1192-1212 (2014).
21. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
22. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat. Genet.* **44**, 955-959 (2012).
23. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369-375 (2012).
24. Unoki, H. *et al.* SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. *Nat. Genet.* **40**, 1098-1102 (2008).
25. Fitzpatrick, G.V., Soloway, P.D. & Higgins, M.J. Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. *Nat. Genet.* **32**, 426-431 (2002).
26. Zeggini, E. *et al.* Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* **316**, 1336-1341 (2007).
27. Shea, J. *et al.* Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. *Nat. Genet.* **43**, 801-805 (2011).
28. Maller, J.B. *et al.* Bayesian refinement of association signals for 14 loci in 3 common diseases. *Nat. Genet.* **44**, 1294-1301 (2012).
29. Jafar-Mohammadi, B. *et al.* A role for coding functional variants in HNF4A in type 2 diabetes susceptibility. *Diabetologia* **54**, 111-119 (2011).
30. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**, 707-713 (2010).
31. Florez, J.C. *et al.* Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene. *Diabetes* **53**, 1360-1368 (2004).
32. Hamming, K.S. *et al.* Co-expression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K⁺ channel. *Diabetes* **58**, 2419-2424 (2009).
33. Nicolson, T.J. *et al.* Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. *Diabetes* **58**, 2070-2083 (2009).
34. Beer, N.L. *et al.* The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. *Hum. Mol. Genet.* **18**, 4081-4088 (2009).
35. Holmkvist, J. *et al.* Common variants in HNF-1 alpha and risk of type 2 diabetes. *Diabetologia* **49**, 2882-2891 (2006).
36. Yamagata, K. *et al.* Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3). *Nature* **384**, 455-458 (1996).
37. Yamagata, K. *et al.* Mutations in the hepatocyte nuclear factor-4 alpha gene in maturity-onset diabetes of the young (MODY1). *Nature* **384**, 458-460 (1996).
38. Gusev, A. *et al.* Partitioning heritability of regulatory and cell-type-specific variants across 11 common diseases. *Am. J. Hum. Genet.* **95**, 535-552 (2014).

39. Soccio, R.E., Tuteja, G., Everett, L.J., Li, Z., Lazar, M.A. & Kaestner, K.H. Species-specific strategies underlying conserved functions of metabolic transcription factors. *Mol. Endocrinol.* **25**, 694-706 (2011).
40. Gaulton, K.J. *et al.* A map of open chromatin in human pancreatic islets. *Nat. Genet.* **42**, 255-259 (2010).
41. Fogarty, M.P., Cannon, M.E., Vadlamudi, S., Gaulton, K.J. & Mohlke, K.L. Identification of a regulatory variant that binds FOXA1 and FOXA2 at the CDC123/CAMK1D type 2 diabetes GWAS locus. *PLoS Genet.* **10**, e1004633 (2014).
42. Manning, A.K. *et al.* A genome-wide approach accounting for body-mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat. Genet.* **44**, 659-669 (2012).
43. Dimas, A.S. *et al.* Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. *Diabetes* **63**, 2158-2171 (2014).
44. Ravassard, P. *et al.* A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. *J. Clin. Invest.* **121**, 3589-3597 (2011).
45. Fadista, J. *et al.* Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. *Proc. Natl. Acad. Sci. USA* **111**, 13924-13929 (2014).
46. Lyssenko, V. *et al.* Common variant in *MTNR1B* associated with increased risk of type 2 diabetes and impaired early insulin secretion. *Nat. Genet.* **41**, 82-88 (2009).
47. Gao, N. *et al.* Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature beta-cell. *Mol. Endocrinol.* **24**, 1594-1604 (2010).
48. Zhou, Y. *et al.* *TCF7L2* is a master regulator of insulin production and processing. *Hum. Mol. Genet.* **23**, 6419-6431 (2014).
49. Lyssenko, V. *et al.* Mechanisms by which common variants in the *TCF7L2* gene increase risk of type 2 diabetes. *J. Clin. Invest.* **117**, 2155-2163 (2007).
50. Gloyn, A.L. *et al.* Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. *N. Engl. J. Med.* **350**, 1838-1849 (2004).
51. Flannick, J. *et al.* Loss-of-function mutations in *SLC30A8* protect against type 2 diabetes. *Nat. Genet.* **46**, 357-363 (2014).
52. Dickson, S.P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D.B. Rare variants create synthetic genome-wide associations. *PLoS Biol.* **8**, e1000294 (2010).
53. Bonnefond, A. *et al.* Rare *MTNR1B* variants impairing melatonin receptor 1B function contribute to type 2 diabetes. *Nat. Genet.* **44**, 297-301 (2012).
54. Zaret, K.S. & Carroll, J.S. Pioneer transcription factors: establishing a competence for gene expression. *Genes Dev.* **25**, 2227-41 (2011).
55. Gao, N., LeLay, J., Vatamaniuk, M.Z., Rieck, S., Friedman, J.R. & Kaestner, K.H. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. *Genes Dev.* **22**, 3435-3448 (2008).
56. Lee, C.S., Friedman, J.R., Fulmer, J.T. & Kaestner, K.H. The initiation of liver development is dependent on Foxa transcription factors. *Nature* **435**, 944-947 (2005).
57. Scott, R.A. *et al.* Large-scale association analyses identify new loci influencing glycaemic traits and provide insight into the underlying biological pathways. *Nat. Genet.* **44**, 991-1005 (2012).

58. Tabassum, R., Chavali, S., Dwivedi, O.P., Tandon, N. & Bharadwaj, D. Genetic variants of FOXA2: risk of type 2 diabetes and effect on metabolic traits in North Indians. *J. Hum. Genet.* **53**, 957-965 (2008).
59. Johnson, M.E., Schug, J., Wells, A.D., Kaestner, K.H. & Grant, S.F. Genome-wide analyses of ChIP-Seq derived FOXA2 DNA occupancy in liver points to genetic networks underpinning multiple complex traits. *J. Clin. Endocrinol. Metab.* **99**, E1580-E1585 (2014).

FIGURE LEGENDS

Figure 1. FOX2A bound sites are a genomic marker of T2D risk variants. (A) Variants in ChIP-seq binding sites for 165 proteins were tested for enrichment of posterior probabilities compared to variants in shifted sites. Variants in FOXA2 ChIP-seq sites were significantly enriched ($p < 0.00030$). (B) FOXA2 ChIP-seq sites were partitioned based on overlap with other genomic features. There was stronger enrichment in: (i) FOXA2 sites overlapping a ChIP-seq site for another protein compared to unique sites; (ii) sites identified in primary islets compared to HepG2 or primary liver cells; and (iii) sites overlapping islet enhancers compared to those that did not (** $p < 0.00030$; * $p < 0.05$). (C) Variants at each signal were tested for FOXA2 enrichment. Nineteen signals had greater enrichment than expected compared to shifted sites; at 15 signals this enrichment was nominally-significant ($p < 0.05$). (D) FOXA2-bound variants disrupting recognition motifs have an increased probability of being causal.

Figure 2. The lone variant in the 99% credible set at the *MTNR1B* locus affects FOXA2-bound enhancer activity. (A) The intronic variant, rs10830963, has 99.8% probability of driving the association signal at the *MTNR1B* locus. This variant overlaps a FOXA2 binding site, and the risk allele G is predicted to create a *de novo* recognition motif, which closely matches the NEUROD1 consensus. (B) Electrophoretic mobility shift assay of a 25bp fragment surrounding both alleles in EndoC- β H1 cell extracts. Proteins were bound to both alleles. In the presence of a NEUROD1 antibody, only the risk allele band was super-shifted, and in the presence of an unlabelled NEUROD1 consensus probe, the signal was competed away. NE: nuclear extract. (C, D) The 224bp sequence surrounding each allele was cloned into a luciferase reporter construct containing a minimal promoter and tested for luciferase activity in (C) EndoC- β H1 and (D) HepG2 cells ($n=3$ for each cell type). Results are presented as mean \pm standard error. The risk allele had significantly increased enhancer activity over the protective allele in both forward and reverse orientations in both cell types.

Table 1. Established T2D susceptibility loci with multiple distinct signals of association at locus-wide significance in the GCTA joint regression model ($p_j < 10^{-5}$).

Locus	Index variant	Chr	Position (b37)	Risk allele	Other allele	Metabochip GCTA joint model 27,206 cases and 57,574 controls			Validation GCTA joint model 19,662 cases and 115,140 controls			Combined GCTA joint model 46,868 cases and 172,714 controls	
						RAF	OR (95% CI)	p_j	RAF	OR (95% CI)	p_j	OR (95% CI)	p_j
DGKB	rs10276674	7	14,922,007	C	T	0.183	1.08 (1.04-1.11)	4.5×10^{-6}	0.216	1.09 (1.05-1.12)	1.3×10^{-6}	1.08 (1.06-1.11)	2.8×10^{-11}
	rs1974620	7	15,065,467	T	C	0.519	1.06 (1.04-1.09)	1.6×10^{-6}	0.515	1.05 (1.03-1.08)	0.00014	1.06 (1.04-1.08)	1.0×10^{-9}
CDKN2B	rs10811660	9	22,134,068	G	A	0.830	1.32 (1.27-1.38)	2.4×10^{-44}	0.817	1.21 (1.17-1.26)	2.6×10^{-21}	1.27 (1.23-1.30)	1.1×10^{-61}
	rs10757283	9	22,134,172	T	C	0.437	1.14 (1.10-1.17)	7.4×10^{-18}	0.436	1.11 (1.07-1.14)	1.3×10^{-10}	1.12 (1.10-1.14)	3.6×10^{-26}
KCNQ1	chr11:2692322:D	11	2,692,322	D	R	0.374	1.08 (1.05-1.10)	3.5×10^{-8}	0.413	1.09 (1.06-1.12)	1.2×10^{-8}	1.08 (1.06-1.10)	2.3×10^{-15}
	rs2283220	11	2,755,548	A	G	0.661	1.06 (1.03-1.09)	0.000016	0.710	1.05 (1.02-1.08)	0.0031	1.06 (1.03-1.08)	2.4×10^{-7}
	rs2237895	11	2,857,194	C	A	0.428	1.08 (1.05-1.11)	6.6×10^{-7}	0.433	1.07 (1.03-1.10)	2.8×10^{-4}	1.07 (1.05-1.10)	5.3×10^{-10}
	rs74046911	11	2,858,636	C	T	0.951	1.32 (1.24-1.40)	1.7×10^{-17}	0.943	1.25 (1.17-1.34)	4.8×10^{-10}	1.29 (1.23-1.35)	9.6×10^{-26}
HNF1A	rs458069	11	2,858,800	G	C	0.707	1.06 (1.03-1.10)	0.00026	0.707	1.07 (1.03-1.11)	0.00085	1.06 (1.04-1.09)	1.0×10^{-6}
	rs1169288	12	121,416,650	C	A	0.334	1.10 (1.07-1.13)	5.4×10^{-10}	0.316	1.08 (1.05-1.12)	2.8×10^{-6}	1.09 (1.07-1.12)	8.1×10^{-15}
	rs1800574	12	121,416,864	T	C	0.027	1.21 (1.11-1.31)	5.2×10^{-6}	0.020	1.23 (1.12-1.35)	0.000026	1.22 (1.14-1.29)	5.1×10^{-10}
MC4R	chr12:121440833:D	12	121,440,833	R	D	0.416	1.06 (1.03-1.09)	0.000028	0.382	1.08 (1.04-1.11)	2.5×10^{-6}	1.07 (1.05-1.09)	2.9×10^{-10}
	chr18:57739289:D	18	57,739,289	D	R	0.234	1.05 (1.02-1.09)	0.00079	0.254	1.07 (1.03-1.10)	0.000059	1.06 (1.04-1.08)	1.9×10^{-7}
GIPR	rs17066842	18	58,040,624	G	A	0.961	1.13 (1.06-1.21)	0.00033	0.948	1.11 (1.04-1.19)	0.0012	1.12 (1.07-1.17)	1.4×10^{-6}
	rs4399645	19	46,166,073	T	C	0.395	1.07 (1.04-1.10)	4.4×10^{-7}	0.441	1.05 (1.01-1.08)	0.0046	1.06 (1.04-1.08)	1.4×10^{-8}
HNF4A ^a	rs2238689	19	46,178,661	C	T	0.425	1.09 (1.07-1.12)	9.7×10^{-12}	0.424	1.07 (1.04-1.10)	9.0×10^{-6}	1.08 (1.06-1.11)	8.3×10^{-16}
	rs1800961	20	43,042,364	T	C	0.034	1.16 (1.09-1.24)	0.000011	0.041	1.16 (1.08-1.25)	0.000051	1.16 (1.10-1.22)	2.3×10^{-9}

Each distinct association signal was represented by an index variant in the GCTA joint regression model on the basis of: (i) summary statistics from a combined meta-analysis of 46,868 cases and 172,714 controls of European ancestry; and (ii) reference genotype data from GoDARTS (3,298 cases and 3,708 controls of European ancestry from the UK) to approximate LD across fine-mapping regions.

Chr: chromosome. RAF: risk allele frequency. OR: odds-ratio for risk allele. CI: confidence interval.

^aThe previously reported T2D GWAS SNP at the *HNF4A* locus (rs4812829) is not included in the fine-mapping region. However, the reported index variant, rs1800961, is independent of the GWAS SNP, and thus represents a novel distinct association signal at this locus.

Table 2. Distinct association signals at established T2D susceptibility loci for which the 99% credible set contains no more than ten variants.

Locus	Index variant	Chr	Position (b37)	Risk allele	Other allele	RAF	p-value	OR (95% CI)	99% credible set			
									SNPs	Interval (bp)	Interval start (bp)	Interval stop (bp)
<i>MTNR1B</i>	rs10830963	11	92,708,710	G	C	0.283	2.9×10^{-12}	1.10 (1.07-1.13)	1	1	92,708,710	92,708,710
<i>TCF7L2</i>	rs7903146	10	114,758,349	T	C	0.260	5.8×10^{-120}	1.39 (1.35-1.43)	3	4,279	114,754,071	114,758,349
<i>KCNQ1</i>	rs74046911	11	2,858,636	C	T	0.951	5.9×10^{-18}	1.33 (1.25-1.42)	3	197	2,858,440	2,858,636
<i>ZBED3</i>	rs7732130	5	76,435,004	G	A	0.278	6.4×10^{-10}	1.09 (1.06-1.12)	5	10,056	76,424,949	76,435,004
<i>CDKN2A-B</i>	rs10757283	9	22,134,172	T	C	0.437	2.8×10^{-19}	1.14 (1.11-1.18)	5	1,007	22,133,645	22,134,651
<i>SLC30A8</i>	rs13266634	8	118,184,783	C	T	0.676	1.3×10^{-18}	1.13 (1.10-1.16)	6	33,133	118,184,783	118,217,915
<i>CDKN2A-B</i>	rs10811660	9	22,134,068	G	A	0.830	7.0×10^{-43}	1.32 (1.27-1.37)	6	1,397	22,132,698	22,134,094
<i>HNF1B</i>	rs4430796	17	36,098,040	G	A	0.455	6.3×10^{-12}	1.09 (1.07-1.12)	7	5,791	36,097,775	36,103,565
<i>CDKAL1</i>	rs35261542	6	20,675,792	A	C	0.280	9.6×10^{-23}	1.15 (1.12-1.18)	8	30,073	20,673,880	20,703,952
<i>GLIS3</i>	chr9:4294707:I	9	4,294,707	I	R	0.360	6.5×10^{-8}	1.07 (1.05-1.10)	10	15,453	4,283,137	4,298,589

Association summary statistics and credible set construction are based on the meta-analysis of MetaboChip studies in 27,206 cases and 57,574 controls of European ancestry. In loci with multiple distinct signals of association, results are presented from exact conditional analysis after adjusting for all other index variants in the fine-mapping region. In loci with a single signal of association, results are presented from unconditional analysis. Chr: chromosome. RAF: risk allele frequency. OR: odds-ratio for risk allele. CI: confidence interval.

Table 3. Motif-disrupting credible set variants in FOXA2 sites.

Locus	Index variant	Motif-disrupting variant	Chr	Position (b37)	Posterior probability (π_c)	Motif-disrupting allele	Chromatin state
<i>MTNR1B</i>	rs10830963	rs10830963	11	92708710	0.998	G	Islet-enhancer, HepG2-enhancer
<i>TCF7L2</i>	rs7903146	rs7903146	10	114,758,349	0.78	T	Islet-enhancer
<i>SLC30A8</i>	rs13266634	rs13266634	8	118,184,783	0.29	T	Islet-enhancer
<i>CDKN2B</i>	rs10811660	rs10811660	9	22,134,068	0.24	A	Islet-enhancer
<i>CDC123</i>	rs11257658	rs11257655	10	12,307,894	0.21	T	Islet-enhancer, HepG2-enhancer
<i>JAZF1</i>	rs1513272	rs849133	7	28,192,280	0.042	T	Islet-enhancer
<i>KCNQ1</i>	rs2283220	rs231907	11	2,752,130	0.031	T	HepG2-enhancer
<i>FTO</i>	rs9927317	rs9940128	16	53,800,754	0.027	G	Islet-enhancer, HepG2-enhancer
<i>FTO</i>	rs9927317	rs9939973	16	53,800,568	0.025	G	Islet-enhancer, HepG2-enhancer
<i>KCNQ1</i>	rs458069	rs78688069	11	2,752,183	0.0006	A	HepG2-enhancer
<i>KCNQ1</i>	rs458069	rs190728714	11	2,813,084	0.00042	G	Islet-enhancer
<i>DGKB</i>	rs10276674	rs7798360	7	15,055,972	0.00005	G	-

Chr: chromosome.

ONLINE METHODS

Ethics statement. All human research was approved by the relevant institutional review boards, and conducted according to the Declaration of Helsinki. All participants provided written informed consent.

MetaboChip imputation and association analysis. We considered a total of 27,206 T2D cases and 57,574 controls from 23 studies from populations of European ancestry (**Supplementary Table 1**), all genotyped with the MetaboChip. Sample and variant quality control was performed within each study (**Supplementary Table 2**). To improve the quality of the genotype scaffold in each study, variants were subsequently removed if: (i) allele frequencies differed from those for European ancestry haplotypes from the 1000 Genomes Project Consortium phase 1 integrated reference panel (March 2012 release)¹⁸ by more than 20%; AT/GC variants had MAF>40% because of potential undetected errors in strand alignment; or (iii) MAF<1% because of difficulties in calling rare variants. Each scaffold was then imputed up to up to the phase 1 integrated reference panel (all ancestries, March 2012 release) from the 1000 Genomes Project Consortium¹⁸, using IMPUTEv2²¹ or minimac²². Within each study, well-imputed variants (IMPUTEv2²¹ info>0.4 or minimac²² r^2 >0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (**Supplementary Table 2**), including principal components to adjust for population structure. Association summary statistics for each variant for each study were corrected for residual population structure using the genomic control inflation factor⁶⁰ obtained from 3,598 independent (r^2 <0.05) QT-interval variants, which were not expected to be associated with T2D⁴ (**Supplementary Table 2**). We then combined association summary statistics for each variant across studies via fixed-effects inverse-variance weighted meta-analysis. The results of the meta-analysis were subsequently corrected by a second round of QT-interval genomic control (λ_{QT} =1.18) to account for structure between studies. Variants were excluded from downstream analyses if they were reported in less than 80% of the total effective sample size, defined as $N_{eff} = 4 \times N_{cases} \times N_{controls} / (N_{cases} + N_{controls})$, thus removing those that were not well imputed in the majority of studies.

Identification of distinct association signals in established GWAS loci. We used GCTA²³ to select index variants in each of the 39 established loci represented on MetaboChip with nominal evidence of association (p_j <0.001) with T2D in an approximate joint regression model. The GCTA model made use of: (i) summary statistics from the fixed-effects meta-analysis MetaboChip studies; and (ii) genotype data for 3,298 T2D cases and 3,708 controls of UK ancestry from GoDARTS as a reference for LD across each fine-mapping region. For comparison, we also obtained association summary statistics for the selected index variants from the GCTA joint regression model on the basis of genotype data from an alternative reference consisting of 4,435 T2D cases and 5,757 controls of Finnish ancestry from FUSION (**Supplementary Table 15, Supplementary Figure 12**). Selected index variants were then carried forward for *in silico* follow-up in validation meta-analysis.

The validation meta-analysis consisted of 19,662 T2D cases and 115,140 controls from 10 GWAS from populations of European ancestry, genotyped with a range of genome-wide arrays (**Supplementary Table 1**). Sample and variant quality control was performed within each study (**Supplementary Table 2**). Each scaffold was then imputed up to the phase 1 integrated reference panel (all ancestries, March 2012 release) from the 1000

Genomes Project Consortium¹⁸, using IMPUTEv2²¹ or minimac²². Within each study, well-imputed variants (IMPUTEv2²¹ info \geq 0.4 or minimac²² $r^2\geq$ 0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (**Supplementary Table 2**), including principal components to adjust for population structure. Association summary statistics for each variant for each study were corrected for residual population structure using the genomic control inflation factor⁶⁰ (**Supplementary Table 2**). We then combined association summary statistics for each variant across studies via fixed-effects inverse-variance weighted meta-analysis.

Association summary statistics for the selected index variants from the MetaboChip and validation meta-analyses were next combined via fixed-effects inverse-variance weighted meta-analysis. In each of the 39 established loci represented on MetaboChip, GCTA²³ was used to select index variants with locus-wide evidence of association ($p_j < 10^{-5}$) in the approximate joint regression model on the basis of: (i) summary statistics from the combined meta-analysis; and (ii) genotype data for 3,298 T2D cases and 3,708 controls from GoDARTS as a reference for LD across each fine-mapping region.

For established loci with multiple index variants selected at locus-wide significance from the GCTA approximate joint regression model in combined meta-analysis, we performed exact conditioning within each MetaboChip study (**Supplementary Table 7**). To obtain the association signal attributed to a specific index variant, high-quality variants (IMPUTEv2²¹ info $>$ 0.4 or minimac²² $r^2 >$ 0.3) were tested for T2D association under an additive model after adjustment for study-specific covariates (**Supplementary Table 2**) and genotypes at other selected index variants in the fine-mapping region. Association summary statistics for each study were corrected for residual population structure using the QT interval genomic control inflation factor obtained in the MetaboChip meta-analysis. For each association signal, summary statistics for each variant were then combined across discovery studies via fixed-effects inverse-variance meta-analysis, and subsequently corrected by a second round of QT-interval genomic control ($\lambda_{QT}=1.18$).

Credible set construction. In an ideal fine-mapping experiment, we would calculate the posterior probability of driving each distinct association signal for all variants mapping to a locus. However, the posterior probability is determined by the association signal effect size of the variant and the corresponding standard error, which is also impacted by the quality of imputation across studies, amongst other factors. To minimise the impact of imputation quality on fine-mapping, we therefore retained only those variants that were directly typed and/or well imputed in at least 80% of the total effective sample size. Assuming that the variant driving an association signal meets these quality criteria, the probability that it would be contained within the 99% credible set would be \sim 0.99.

For each distinct signal, we first calculated the posterior probability, π_{Cj} , that the j th variant is driving the association, given by

$$\pi_{Cj} = \frac{\Lambda_j}{\sum_k \Lambda_k},$$

where the summation is over all retained variants in the fine-mapping region. In this expression, Λ_j is the approximate Bayes' factor⁶¹ for the j th variant, given by

$$\Lambda_j = \sqrt{\frac{V_j}{V_j + \omega}} \exp \left[\frac{\omega \beta_j^2}{2V_j(V_j + \omega)} \right],$$

where β_j and V_j denote the estimated allelic effect (log-OR) and corresponding variance from the meta-analysis across MetaboChIP studies. In loci with multiple distinct signals of association, results are presented from exact conditional meta-analysis after adjusting for all other index variants in the fine-mapping region. In loci with a single association signal, results are presented from unconditional meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken here to be 0.04⁶¹. The 99% credible set²⁹ for each signal was then constructed by: (i) ranking all variants according to their Bayes' factor, Λ_j ; and (ii) including ranked variants until their cumulative posterior probability of driving the association attained or exceeded 0.99.

Genomic annotation data and enrichment analyses. We obtained genomic annotation data for transcription factor binding sites (TFBS) assayed through ChIP experiments from multiple sources. We used sites from the ENCODE Project Consortium¹⁰ for 161 proteins available from the UCSC human genome browser. We also obtained raw ChIP and input sequence data for additional factors assayed in primary pancreatic islets¹⁴. We then processed these additional factors using protocols employed by the ENCODE Project Consortium¹⁰. First, sequence reads were aligned to the human genome (hg19) using BWA⁶² with sex-specific references, and were then converted to BAM files using SAMtools⁶³ after removing duplicate and non-uniquely mapped reads. Binding sites were called from reads of each replicate, as well as reads pooled across all replicates, using SPP⁶⁴. Raw sites from each replicate of a protein were compared using an irreproducible discovery rate⁶⁵ (IDR) threshold of 0.02. The resulting number of sites passing this IDR threshold was then used to filter the pooled sites of a protein. The set of sites were further filtered for artefacts using a blacklist of genomic regions from the ENCODE Project Consortium. Sites from all sources for each protein, including ENCODE, were then combined. The complete set of 165 proteins employed in these analyses is presented in **Supplementary Table 11**. In addition, we obtained FOXA2 ChIP-seq sites that were previously identified in human liver³⁹ and lifted their positions to hg19.

We obtained annotation data for five histone modifications (H3K4me1, H3K4me3, H3K27ac, H3K36me3, and H3K27me3) and CTCF binding assayed from ChIP experiments. We used data from 9 cell types from ENCODE¹⁰ (Gm12878, K562, Hepg2, Hsmm, Huvec, Nhek, Nhlf, h1Hesc, and Hmec); we also obtained raw ChIP data assayed in primary pancreatic islets¹⁴ and pre-mature and mature human adipose stromal cells⁶⁶. We mapped reads to hg19 using BWA⁶², and used the resulting mapped reads from these 12 cell types as input to ChromHMM⁶⁷. We assigned states based on the following chromatin signatures: active promoter (H3K4me3 and H3K27ac); strong enhancer 1 (H3K4me3, H3K27ac, and H3K4me1); strong enhancer 2 (H3K27ac and H3K4me1); weak enhancer (H3K4me1); poised promoter (H3K27me3, H3K4me3, and H3K4me1); repressed (H3K27me3); insulator (CTCF); and transcription (H3K36me3). For each cell type, we pooled the three enhancer states into one enhancer category, and the two promoter states into one promoter category. We also identified long non-coding RNA data from the Human Body Map (UCSC genome browser) and from pancreatic islets⁶⁸.

For each genomic annotation, we tested for overall enrichment of the posterior probability that overlapping variants in the 99% credible sets are driving distinct association signals (π_c). We first calculated the mean posterior probability (mean π_c) over the set of variants overlapping a given annotation. We then generated a null distribution of the mean posterior probability (mean π_c) by: (i) shifting the genomic locations of binding sites a random distance within 100kb in either direction; (ii) recalculating the mean posterior probability for 99% credible set variants overlapping shifted sites; and (iii) repeating this procedure 100,000 times. We estimated the fold-enrichment of each overlap by calculating the expected null posterior probability, and dividing the observed probability by the expected probability. We calculated a p -value for the enrichment by the proportion of permutations for which the expected posterior probability of driving the association signal was greater than or equal to that observed. We considered cell type annotations to be significantly enriched if the p -value was less than $0.05/37 = 0.0014$ (Bonferroni correction for 37 annotations). We considered TFBS annotations to be significantly enriched if the p -value was less than $0.05/165 = 0.00030$ (Bonferroni correction for 165 factors). We next partitioned binding sites into those that are “shared” with another factor (i.e. genomic interval intersects a site for at least one other factor), and those that are “unique”. We also partitioned binding sites based on overlap with islet enhancer elements. For each factor with significant enrichment across all credible sets (FOXA2), we applied the same enrichment analysis, but restricted to credible set variants for each distinct association signal, separately.

We assessed the evidence for intersection in FOXA2 ChIP-seq sites from islets¹⁴, HepG2¹⁰, and liver³⁹, genome-wide and overlapping credible set variants, using BEDtools⁶⁹.

Motif analysis. We conducted recognition motif enhancement analyses for the set of FOXA2 ChIP-seq binding sites. First, we obtained repeat-masked genomic sequence underlying each site using the UCSC human genome browser. We scanned sequences for enrichment in these motifs using MEME-ChIP⁷⁰, which uses up to 100bp surrounding the mid-point of each site. This resulted in 198 enriched motifs with E-value (expected number of hits) less than 0.05 (**Supplementary Table 16**). We compared each motif to those known from JASPAR⁷¹, ENCODE¹⁰, and Homer⁷² using Tomtom⁷³.

Second, we identified variants in FOXA2 ChIP-seq sites predicted to disrupt an enriched recognition motif by: (i) scanning a 25bp of sequence flanking each variant allele using FIMO⁷⁴ ($p < 0.0001$); and (ii) retaining variants in highly conserved positions (entropy less than 0.5). For the 12 variants at FOXA2-enriched signals disrupting at least one recognition motif (**Table 3, Supplementary Table 14**), we compared their posterior probabilities of driving the association (π_c) with those for non-disrupting variants in FOXA2 ChIP-seq sites at the same signals using a two-sided Wilcoxon rank-sum test.

Electrophoretic mobility shift assays. EMSA was performed using nuclear extracts from human HepG2 and EndoC- β H1 cells. HepG2 cells were the generous gift of the Ratcliffe laboratory⁷⁵ and authenticated by genotyping in the MHC region. Endo- β H1 cells were obtained from Endocells and have been previously authenticated⁴⁴. Both cell lines were tested and found negative for mycoplasma contamination. Nuclear extracts were incubated with ³²P gamma-ATP end-labeled double-stranded DNA probes (PerkinElmer, MA). The forward strand probe sequences used are presented in **Supplementary Table 17**.

For each lane of the EMSA, 5µg of nuclear extract was incubated with 100 fmol labeled probes in a 10ul binding reaction containing 10mM Tris-HCl pH7.5, 4% glycerol, 1mM MgCl₂, 0.5mM EDTA, 0.5mM DTT, 50mM NaCl and 1µg poly(dI-dC). For competition assays unlabeled probe at 100-fold excess was added to the binding reaction before addition of labeled probes. For super-shift assays the nuclear extract was pre-incubated with 1µg antibody for 30 minutes on ice before the probe was added. The following antibodies were used: anti-NEUROD1 (sc-1084X, Santa Cruz Biotechnology, Texas), anti-PTF1A (sc-98612X, Santa Cruz Biotechnology, Texas), anti-HNF3B (FOXA2) (sc-6554X, Santa Cruz Biotechnology, Texas), anti-YY1 (sc281X, Santa Cruz Biotechnology, Texas), anti-TAL1 (sc12984X, Santa Cruz Biotechnology, Texas), normal rabbit Ig (sc-2027, Santa Cruz Biotechnology, Texas), normal goat Ig (sc-2028, Santa Cruz Biotechnology, Texas).

Luciferase activity. We synthesised 224bp nucleotide sequences containing either the risk or protective allele of the *MTNR1B* enhancer sequence rs10830963 in either the forward or reverse orientation by GeneArt (Life Technologies). Complementary single-stranded oligos were then annealed and sub-cloned into the minimal promoter-driven luciferase vector pGL4.23 (Promega) using NheI and XhoI. Isolated clones were verified by sequencing.

For luciferase assays, human liver HepG2 and human beta-cell EndoC-βH1⁴⁵ cells were counted and seeded into 24 well trays (Corning) at 1.5x10⁵ (HepG2) or 1.4x10⁵ (EndoC-βH1) cells/well. Transfections were performed in triplicate with either Lipofectamine 2000 (HepG2) or Fugene 6 (EndoC-βH1) as per manufacturer's instructions. Cells were transfected with 700ng pGL4.23 DNA containing the protective or risk *MTNR1B* enhancer sequence in either the forward or reverse orientation, or an equivalent amount of empty vector DNA, plus 10ng pRL-SV40 DNA (Promega) as a transfection control, per well. Cells were lysed 48 hours post-transfection and analysed for Firefly and *Renilla* luciferase activities using the Dual Luciferase Assay System (Promega) as per manufacturer's instructions, in half-volume 96 well tray format on an Enspire Multimode Plate Reader (Perkin Elmer). Firefly luciferase activity was normalised to *Renilla* luciferase activity for each well, and the results expressed as a mean normalised activity relative to empty vector-transfected cells. All experiments were performed three times in triplicate. A two-sided unpaired t-test was used to compare luciferase activity between alleles.

Mouse gene expression analysis. We obtained fold-changes in pancreatic islet gene expression in wild type compared to *Foxa1/Foxa2*-null mice⁴⁷. We used ENSEMBL to map mouse genes to human orthologs. We filtered for human genes annotated as protein coding in GENCODE. This filtering resulted in 4,629 human protein coding genes for analysis.

First, we calculated the genomic interval spanned by the variants in each credible set. We expanded this interval for 500kb on either side, and identified the set of genes overlapping this region using BEDtools⁶⁹. To account for syntenic differences in gene order between species, we retained only those genes that were: (a) on the same chromosome; and (b) in exactly the same relative order in both mouse and human genomes. At the *GIPR* locus, one of the genes was ordered differently and thus removed from the analysis. At two loci, *KCNJ11* and *HNF1A*, at least one of the genes was located on a different part of the same chromosome, and at another locus, *GCK*, genes were located on different chromosomes. For these three loci, we retained only those genes that were at the same chromosomal location to the interval covered by the credible set for the association signal

for that locus (by lifting over from hg19 to mouse build mm10). Second, for each distinct association signal, we identified the closest gene to the index variant using BEDtools⁶⁹. We then partitioned distinct association signals into those with evidence for enriched FOXA2 binding (fold-enrichment >1) and those without, counting each gene only once in a given group. For each analysis, we converted the fold-changes to percentages, and compared the percent change in expression using a one-sided Wilcoxon rank-sum test between genes in each partition and all 4,629 protein coding genes.

60. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997-1004 (1999).
61. Wakefield, J.A. Bayesian measure of the probability of false discovery in genetic epidemiology studies. *Am. J. Hum. Genet.* **81**, 208-227 (2007).
62. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinf.* **25**, 1754-1760 (2009).
63. Li, H. *et al.* The sequence alignment/map format and SAMtools. *Bioinf.* **25**, 2078-2079 (2009).
64. Kharchenko, P.V., Tolstorukov, M.Y. & Park, P.J. Design and analysis of ChIP-seq experiments for DNA-binding proteins. *Nat. Biotechnol.* **26**, 1351-1359 (2008).
65. Li, Q., Brown, J.B., Huang, H. & Bickel, P.J. Measuring reproducibility of high-throughput experiments. *Ann. App. Stat.* **5**, 1752-1779 (2011).
66. Mikkelsen, T.S. *et al.* Comparative epigenomic analysis of murine and human adipogenesis. *Cell* **143**, 156-169 (2010).
67. Ernst, J. & Kellis, M. Discovery and characterization of chromatin states for systematic annotation of the human genome. *Nat. Biotechnol.* **28**, 817-825 (2010).
68. Morán, I. *et al.* Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. *Cell Metab.* **16**, 435-448 (2012).
69. Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinf.* **26**, 841-842 (2010).
70. Machanick, P. & Bailey, T.L. MEME-ChIP. Motif analysis of large DNA datasets. *Bioinf.* **27**, 1696-1697 (2011).
71. Mathelier, A. *et al.* JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. *Nucleic Acids Res.* **42**, D142-D147 (2014).
72. Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and b-cell identifies. *Mol. Cell* **38**, 576-589 (2010).
73. Bailey, T.L. *et al.* MEME Suite: tools for motif discovery and searching. *Nucleic Acids Res.* **37**, W202-W208 (2009).
74. Grant, C.E., Bailey, T.L. & Noble, W.S. FIMO: scanning for occurrences of a given motif. *Bioinf.* **27**, 1017-1018 (2011).
75. Pugh, C.W., Tan, C.C., Jones, R.W. & Ratcliffe, P.J. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. *Proc. Natl. Acad. Sci. USA* **88**, 10553-10557 (1991).

COMPETING FINANCIAL INTERESTS

V.Steinhorsdottir, G.T., A.K., U.T., and K.Stefansson are employed by deCODE Genetics/Amgen inc. I.B. and spouse own stock in GlaxoSmithKline and Incyte.